← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Theratarget
South Salt Lake City, UT
$3,239,367
Total funding
6
Grants
Funding over time
peak $944.5K · FY2010–19$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,239,367 · 6
By mechanism
R42$2,491,063 · 2
R41$748,304 · 4
Investigators at Theratarget
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$694,475
R42 · FY2017 · CA
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer$502,857
R42 · FY2014 · CA
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer$492,378
R42 · FY2015 · CA
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$400,462
R42 · FY2016 · CA
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$399,441
R42 · FY2018 · CA
Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms$250,000
R41 · FY2017 · NS
Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms$150,000
R41 · FY2018 · NS
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer$148,304
R41 · FY2011 · CA
Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer$100,000
R41 · FY2010 · CA
In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$100,000
R41 · FY2012 · CA
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma$1,450
R42 · FY2019 · CA